IL13Rα2/B7H3/CD58 (Aleta Biotherapeutics)

N/A

Report date: 2026/05/18 20:02:07

Base Information

Drug NameIL13Rα2/B7H3/CD58 (Aleta Biotherapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > T cell engagers

Mechanisms of ActionAnti-CD276Lymphocyte function-associated antigen 3 modulatorsAnti-IL13RA2

TargetsCD276 antigenLymphocyte function-associated antigen 3Interleukin-13 receptor subunit alpha-2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAleta BioTherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAleta BioTherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A